Lv64
2514 积分 2022-10-17 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
16天前
已完结
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
17天前
已完结
Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
29天前
已完结
《血友病治疗中国指南(2025年版)》指南解读
30天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
FⅧa模拟物治疗血友病A的研究进展
2个月前
已完结
重组人凝血因子Ⅶa临床用药指导原则（2026年版）
2个月前
已完结
A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa–transferrin fusion protein, in warfarin-pretreated healthy male participants
3个月前
已关闭
Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL
3个月前
已完结
皖公网安备34019202002308
